In short
A groundbreaking clinical trial is underway to evaluate the safety and potential effectiveness of ISTEM-01, a novel treatment for retinitis pigmentosa caused by genetic mutations. This study aims to assess the implantation of human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in patients with this degenerative eye condition. The trial offers hope for those affected by this rare disease and may pave the way for innovative tissue replacement therapies in ophthalmology.
At a glance
- Study Type
- Phase 1/2, open-label safety, tolerability, and preliminary efficacy study
- Intervention
- ISTEM-01 (hESC-derived RPE cells) implantation into one eye
- Target Condition
- Retinitis pigmentosa due to monogenic mutation
- Primary Objective
- Assess safety and tolerability over 56 weeks post-implantation
- Secondary Objectives
- Evaluate patch placement, assess preliminary efficacy, long-term safety and efficacy up to 5 years
- Key Eligibility Criteria
- Age 18-65, confirmed genetic diagnosis, specific visual acuity requirements
- Primary Endpoint
- Incidence of adverse events or serious adverse events
- Secondary Endpoints
- Changes in visual function, retinal imaging, ERG, microperimetry
- Follow-up Duration
- 56 weeks for primary endpoint, up to 5 years for long-term follow-up
What is ISTEM-01?
ISTEM-01 is an innovative medical treatment currently being studied for patients with a specific type of eye disease called retinitis pigmentosa. It is classified as a cell therapy product, which means it uses living cells as a treatment. Specifically, ISTEM-01 is made up of special cells called Retinal Pigment Epithelium (RPE) cells that are derived from human embryonic stem cells.
The treatment comes in the form of a medicated patch that is placed under the retina (the light-sensitive tissue at the back of the eye) through a surgical procedure. This method of application is known as sub-retinal administration.
Target Condition: Retinitis Pigmentosa
Retinitis pigmentosa is a group of rare genetic disorders that involve a breakdown and loss of cells in the retina. This condition can lead to vision loss and, in some cases, blindness. ISTEM-01 is specifically being studied for patients with retinitis pigmentosa caused by a monogenic mutation, which means the condition is caused by a change in a single gene.
How ISTEM-01 Works
ISTEM-01 aims to replace damaged or lost retinal pigment epithelium cells in patients with retinitis pigmentosa. These cells play a crucial role in supporting and nourishing the light-sensitive cells of the retina (photoreceptors). By implanting healthy RPE cells derived from stem cells, researchers hope to slow down or potentially reverse some of the vision loss associated with retinitis pigmentosa.
Clinical Trial Details
ISTEM-01 is currently being studied in a Phase 1/2 clinical trial. This means it's in the early stages of testing in humans to evaluate its safety and get initial data on its effectiveness. Here are some key details about the trial:
- The trial is open-label, which means both the researchers and participants know which treatment is being used.
- It aims to assess the safety and tolerability of ISTEM-01 implantation over a period of 56 weeks (about 1 year) after the treatment.
- The study will also look at the placement and position of the patch in the eye and evaluate any preliminary signs of effectiveness.
- Participants will be followed for up to 5 years after treatment to assess long-term safety and effectiveness.
Eligibility Criteria
Not everyone with retinitis pigmentosa can participate in this clinical trial. Some key eligibility criteria include:
- Confirmed diagnosis of retinitis pigmentosa based on a genetic test showing a mutation in specific genes (RPE65, LRAT, or MerTK).
- Age between 18 and 65 years old.
- Specific levels of visual acuity (a measure of how clearly a person can see), which differ depending on which group (cohort) of the study a patient might join.
There are also several factors that would exclude someone from participating, such as allergies to products used in the study, prior gene or cell therapy treatments, or certain other medical conditions.
Safety and Efficacy Evaluation
The researchers will be closely monitoring participants for any side effects or adverse events related to the treatment. They will also be looking at several measures to evaluate if the treatment is working, including:
- Changes in visual acuity (how clearly a person can see).
- Changes in visual field (how wide an area a person can see).
- The function of the retina and RPE cells using special tests like electroretinography (ERG).
- The survival of photoreceptors (light-sensitive cells in the retina) over the implanted RPE cells.
Potential Benefits
While it's important to remember that ISTEM-01 is still in the early stages of research, the hope is that this treatment could potentially slow down or even partially reverse vision loss in people with retinitis pigmentosa. However, more research is needed to determine its effectiveness and safety.
If you have retinitis pigmentosa and are interested in this or other clinical trials, it's important to discuss your options with your eye doctor or a specialist in retinal diseases.